Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population.

Authors :: Van de Wyngaert Z
Carpentier B
Pascal L
Lionne-Huyghe P
Leduc I
Srour M
Vasseur M
Demarquette H
Terriou L
Herbaux C
Manier S
Bossard JB
Barbieux S
Chauvet P
Willaume A
Nudel M
Bories C
Gibier JB
Facon T
Boyle EM
Source :: British journal of haematology [Br J Haematol] 2020 Feb; Vol. 188 (3), pp. e24-e27. Date of Electronic Publication: 2019 Nov 19.
Publication Year :: 2020

Subjects :: Aged
Cost of Illness
Female
Humans
Male
Middle Aged
Retrospective Studies
Antibodies, Monoclonal administration & dosage
Immunoglobulin Light-chain Amyloidosis drug therapy
Infections drug therapy

Full Text Access

Tools